News
Towards relevant naming schemes for T cell receptor and immunoglobulin germline genes
Naming of immunoglobulin and T cell receptor genes is currently based on their perceived relative location in the genome. This principle is very attractive but greatly challenged by recent genomic studies as we become aware of the extensive structural diversity of these loci. In particular when we intend to name genes beyond the well-studied human [...]
Researchers at the Department of Immunotechnology attract key project grants of 2025
Prof. Mats Ohlin, Prof. Malin Lindstedt and Ass. Prof. Anna Gerdtsson obtained in total 16 mil SEK for their research projects by the Swedish Research Council and Swedish Cancer Society and VR in 2025.
Major donation to research team headed by Prof. Carl Borrebaeck at the Dept. of Immunotechnology
A research team headed by Prof. Carl Borrebaeck of the Dept. of Immunotechnology in collaboration with research teams at the Faculty of Medicine (Lund University), the Swiss Cancer Center, and EPFL in Lausanne has received a donation of 420 MSEK from the Mrs Berta Kamprad's foundation to promote research in the field of immuno-oncology.
SciLifeLab DDD at the Department of Immunotechnology will present its processes and academic collaborations
The SciLifeLab Drug Discovery and Development Platform's Display and Selection Technologies unit in Lund will present its offer for therapeutic antibody development to academic users. Join us in Belfragesalen at BMC on February 26th, 2025 at 15.00. Please register! Welcome!
Dr Peter Ellmark join the Dept. of Immunotechnology as Adjunct Professor
Peter Ellmark is Chief Scientific Officer at Alligator Bioscience, Lund, and he has more than 20 years’ experience of developing antibodies for immunotherapy of cancer. He holds a PhD and an Associate Professorship in Immunotechnology. He brings valuable expertise from biotech industry and his activities at the Department of Immunotechnology will [...]
Advancing Preclinical Safety: Leveraging AOPs for Immunomodulatory Therapies and ATMPs
Prof. Malin Lindstedt and Dr. Christina Sakellariou has contributed with four key publications on a special issue of the Journal of Immunotoxicology on the “Immune-related adverse outcome pathways for immunomodulatory biotherapeutics”.
The Swedish Cancer Society funds research at the Dept. of Immunotechnology
The Cancer Target research team headed by Prof. Sara Ek has been awarded 3 MSEK by the Swedish Cancer Society to carry out a project entitled "A cellular and molecular dissection of the lymphoma tumor immune microenvironment to understand and address treatment resistances".
Antibody specificity identified at the Dept. of Immunotechnology is heading towards clinical trials
Antibody AKIR001, the precursor of which was isolated at the SciLifeLab unit of the Dept. of Immunotechnology, in collaboration with Prof. Marika Nestor of Uppsala University, and other units of the SciLifeLab Drug Discovery and Development platform is heading for first-in-human clinical trials. For more information read additional information from [...]
Winner of pitch prize at Engineering Health retreat
Asger Meldgaard Frank of the Dept. of Immunotechnology wins the pitch price at the Faculty of Engineering's profile area Engineering Health 2024 retreat. Great start for the new Biomolecular and Cellular Technology focus area within the profile area.
Immunotechnology research on the cover of Blood Advances
The cancertarget group, led by Prof. Sara Ek, is applying joint strategies for image and spatial omic analysis to reveal novel insight on tumor and immune cell interactions. In the recent issue of Blood Advances, our paper was featured on the journal's cover. In the article, we describe how macrophage polarization impacts treatment response in [...]